Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann-Pick Type C disease among intellectually disabled using discrete event simulation.
暂无分享,去创建一个
Carlo Marra | Sylvia Stockler | Clara D M van Karnebeek | C. V. van Karnebeek | C. Marra | G. Sinclair | S. Sirrs | S. Stockler | Sandra Sirrs | Graham Sinclair | T. Mohammadi | Tima Mohammadi | Nicole Tsao | N. Tsao
[1] A. Akopian. Regulation of nociceptive transmission at the periphery via TRPA1-TRPV1 interactions. , 2011, Current pharmaceutical biotechnology.
[2] Y. Chien,et al. Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat , 2012, Orphanet Journal of Rare Diseases.
[3] F. Sedel,et al. Development of a Suspicion Index to aid diagnosis of Niemann-Pick disease type C , 2012, Neurology.
[4] M. Patterson,et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study , 2007, The Lancet Neurology.
[5] S. Ashwal,et al. Evidence Report: Genetic and metabolic testing on children with global developmental delay , 2011, Neurology.
[6] P. Meikle,et al. Prevalence of lysosomal storage disorders. , 1999, JAMA.
[7] W. Pavan,et al. Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type C , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[8] G. Francis,et al. The National Niemann–Pick C1 disease database: Report of clinical features and health problems , 2007, American journal of medical genetics. Part A.
[9] F. Sedel,et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. , 2012, Molecular genetics and metabolism.
[10] M. Pineda,et al. New agents and approaches to treatment in Niemann-Pick type C disease. , 2011, Current pharmaceutical biotechnology.
[11] D. Ory. Niemann-Pick type C: a disorder of cellular cholesterol trafficking. , 2000, Biochimica et biophysica acta.
[12] Ling-Hsiang Chuang,et al. Mapping for economic evaluation. , 2012, British medical bulletin.
[13] C. V. van Karnebeek,et al. The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource. , 2014, Molecular genetics and metabolism.
[14] R. Hennekam,et al. Etiology of mental retardation in children referred to a tertiary care center: a prospective study. , 2005, American journal of mental retardation : AJMR.
[15] N. Baumann,et al. The adult form of Niemann-Pick disease type C. , 2006, Brain : a journal of neurology.
[16] C. Doran,et al. How much does intellectual disability really cost? First estimates for Australia , 2012, Journal of intellectual & developmental disability.
[17] R. Oostenbrink. Diagnostic and prognostic research in paediatrics: Children with meningeal signs , 2001 .
[18] M. Patterson,et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. , 2010, Molecular genetics and metabolism.
[19] Lisa G Shaffer,et al. Genetic basis of intellectual disability. , 2013, Annual review of medicine.
[20] J. Caro,et al. Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.
[21] M. Patterson,et al. Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C , 2010, Journal of child neurology.
[22] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[23] M. O'Callaghan,et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. , 2010, Molecular genetics and metabolism.
[24] J. Vance,et al. Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin , 2014, Journal of Lipid Research.
[25] W. Henley,et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. , 2012, Health technology assessment.
[26] Anneliese O. Speak,et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma[S] , 2011, Journal of Lipid Research.
[27] G. Besley,et al. The natural history of Niemann–Pick disease type C in the UK , 2007, Journal of Inherited Metabolic Disease.
[28] C. V. van Karnebeek,et al. The treatable intellectual disability APP www.treatable-id.org: A digital tool to enhance diagnosis & care for rare diseases , 2012, Orphanet Journal of Rare Diseases.
[29] E. Hunsche,et al. Cost of illness associated with Niemann-Pick disease type C in the UK , 2009, Journal of medical economics.
[30] F. Sedel,et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. , 2009, Molecular genetics and metabolism.
[31] T. Irie,et al. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. , 2013, Molecular genetics and metabolism.
[32] Marie T. Vanier,et al. Niemann–Pick disease type C , 2003, Clinical genetics.
[33] R. A. Wevers,et al. The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.
[34] M. Baumgartner,et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. , 2009, Molecular genetics and metabolism.
[35] O. Amaral,et al. Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.
[36] C. Fischer,et al. Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators , 2013, Orphanet Journal of Rare Diseases.
[37] D. Balding,et al. Genetic screening for Niemann–Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study , 2013, Human molecular genetics.